Key Highlights

  • Adjusted diluted EPS was $0.77, up from $0.60 a year earlier, against a screened estimate of $0.65.
  • Net sales rose 5% to $149.6 million from $143.0 million.
  • Adjusted gross margin reached 42.2%, up 330 basis points from 38.9%.
  • Full-year adjusted EPS guidance was raised to $2.78 to $2.88 from $2.55 to $2.70.
  • Free cash flow was $41.1 million, versus $24.2 million a year earlier.

CTS Earnings: Did a Guidance Raise and Record Margins Change the Outlook?

CTS (NYSE:CTS) reported third-quarter results on Tuesday, October 27, with net sales of $149.6 million, up 5% from $143.0 million. Adjusted diluted EPS was $0.77 versus $0.60 a year earlier, which compares with a screened estimate of $0.65 and a surprise of 17.86% as screened.

Management raised its full-year 2026 outlook, assuming current market conditions continue. Sales are now expected at $580 million to $590 million, up from $565 million to $585 million, and adjusted diluted EPS at $2.78 to $2.88, up from $2.55 to $2.70.

CTS makes sensors, actuators and electronic components for aerospace and defense, industrial, medical and transportation customers, with plants in North America, Europe and Asia. The release did not provide a next-quarter forecast.

CTS Margins: How Did Profitability Reach Record Levels?

Adjusted gross margin was 42.2%, up 330 basis points from 38.9%, and adjusted EBITDA margin was 24.7%, up 90 basis points from 23.8%. Adjusted operating earnings were $27.5 million, or 18.4% of sales, versus $24.8 million, or 17.3%.

On a GAAP basis, net earnings were $17.8 million, or $0.61 per diluted share, compared with $13.7 million, or $0.46. GAAP operating earnings were $25.5 million, or 17.1% of sales, versus $20.9 million, or 14.6%.

The GAAP figures include a pretax insurance recovery of $12.5 million, which was excluded from adjusted results. Discrete tax items of $12.7 million, mainly a valuation allowance on foreign tax credits and changes to uncertain tax positions, along with $1.2 million of acquisition-related costs and $0.2 million of environmental charges, were also excluded.

CTS End Markets: Is Diversification Driving the Growth?

The company reports two end-market groups rather than formal segments. Diversified end markets, which cover industrial, aerospace and defense, and medical, grew sales 7% and now account for 60% of total sales. Transportation sales rose 2%.

Management described the Millar acquisition as advancing its diversification strategy, particularly in medical. The release disclosed no terms for the deal.

For the first nine months, sales were $433.6 million versus $404.0 million, GAAP diluted EPS was $1.87 versus $1.52, and adjusted diluted EPS was $2.13 versus $1.61. Nine-month adjusted EBITDA margin was 24.4% versus 22.5%.

CTS Cash Flow: What Does the Balance Sheet Support?

Operating cash flow was $43.5 million versus $29.0 million, and capital expenditures fell to $2.4 million from $4.8 million. Free cash flow was $41.1 million versus $24.2 million, and $82.3 million over nine months versus $60.4 million.

Cash and equivalents stood at $143.9 million at September 30, up from $82.3 million at the end of 2025, against long-term debt of $55.0 million. Shareholders' equity was $586.7 million versus $551.8 million.

The quarterly dividend was unchanged at $0.04 per share. The release did not state repurchase amounts, though weighted average basic shares fell to 28.5 million from 29.3 million.

What to Watch Next After the CTS Guidance Raise?

Investors will look for fourth-quarter results to test the raised full-year ranges, which imply further sales and earnings progress. The pace of diversified end-market growth, transportation demand and the contribution from Millar will frame how long the margin gains can hold.